Stock screener

DNLI

Conviction 87HealthcareScan · Mon, Aug 10, 2026
DNLI$25.00+0.68%
ResistanceSupportVol 14
63 bars
Vol MA14 1.57M
May 11May 28Jun 16Jul 6Jul 23Aug 10
Denali Therapeutics Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.denalitherapeutics.com
Price25.00
Change+0.68%
Gap-0.77%
Rel volume1.35×
Avg volume1.8M
Avg $ vol42.53M
SMA 2023.69
SMA 5023.48
SMA 20020.07
Price vs 50+6.48%
Price vs 200+24.54%
MA stackbullish
50/200 cross
Supertrenddown · 26.43
RSI (14)58
MACD hist0.10
MACD crossbull · 2d
Stoch %K / %D76 / 79
ADX (14)18
+DI / −DI25 / 17
RSI divergence
MACD divergenceBullish
ATR %+4.33%
ADR %4.77%
52w high27.21
52w low12.75
From 52w high-8.12%
Above 52w low+96.08%
New 52w highNo
SqueezeOff
Bollinger width11.87%
%B0.97
Donchian pos69.37%
Donchian high26.32
Donchian low22.01
AVWAP (52w high)24.03
vs AVWAP high+4.02%
AVWAP (52w low)19.70
vs AVWAP low+26.93%
OBV trendFlat
Chaikin MF (20)0.07
Today vs 20d1.35×
Avg vol (14d)1.57M
Avg vol (20d)1.8M
Avg $ vol (20d)42.53M
Market cap4B
RS 3m (vs SPY)+20.28%
RS 6m (vs SPY)+9.91%
RS line new highNo
Trend template8/8
Technical rank72.5
1 week+7.99%
1 month-2.65%
3 months+27.42%
6 months+18.60%
1 year+75.69%
YTD+53.66%
P/E-7.80
P/B4.78
P/S
P/FCF-9.47
EPS-2.97
Div yield
ROE-61.37%
ROA-44.26%
Debt/Eq
Current8.37
EV/EBITDA-6.97
Gross margin
Net margin
Rev growth
EPS growth-21.23%
Price target36.31
Target upside45.24%
Analyst ratingBuy
Institutional105.33%
Ent. value3.79B
Revenue3.6M
Net income-127.55M
Gross profit
Free cash flow-422.1M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out158.71M
Employees507
ListedFri, Dec 8, 2017
Free float128.21M
Float %87.4%
Short interest16.04M
Days to cover8.4d
Short volume68.8%
Squeeze score75 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.68 vs −$0.72
Last surprise+5.6% beat
Setup gradeA
Conviction87 / 100
Pattern quality
Tech rank72.5 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance27.05
Support22.27
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in DNLI

All disclosures →
No recent disclosed trades by Congress in DNLI. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DNLI · 10 buys

InsiderSideShares
Baker Brothers Life Sciences LP
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER JULIAN
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER FELIX
Director · Common Stock · 2026-06-03
Grant6.41K
BAKER JULIAN
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Baker Bros. Advisors (GP) LLC
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
BAKER BROS. ADVISORS LP
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
BAKER BROS. ADVISORS LP
Director · Non-Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Baker Brothers Life Sciences LP
Director · Non- Qualified Stock Option (right to buy) · 2026-06-03
Grant19.23K
Schenkein David P
Director · Common Stock · 2026-06-03
Grant6.41K
Cook Jennifer E.
Director · Stock Option (right to buy) · 2026-06-03
Grant19.23K

SEC filings

EDGAR filings in DNLI · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.